Literature DB >> 35313331

Porcupine Inhibition Disrupts Mitochondrial Function and Homeostasis in WNT Ligand-Addicted Pancreatic Cancer.

Kristina Y Aguilera1, Thuc Le2,3, Rana Riahi1, Anna R Lay1, Stefan Hinz4, Edris A Saadat1, Ajay A Vashisht5, James Wohlschlegel5, Timothy R Donahue1,2,3,6, Caius G Radu2,3, David W Dawson1,7.   

Abstract

WNT signaling promotes pancreatic ductal adenocarcinoma (PDAC) through diverse effects on proliferation, differentiation, survival, and stemness. A subset of PDAC with inactivating mutations in ring finger protein 43 (RNF43) show growth dependency on autocrine WNT ligand signaling and are susceptible to agents that block WNT ligand acylation by Porcupine O-acyltransferase, which is required for proper WNT ligand processing and secretion. For this study, global transcriptomic, proteomic, and metabolomic analyses were performed to explore the therapeutic response of RNF43-mutant PDAC to the Porcupine inhibitor (PORCNi) LGK974. LGK974 disrupted cellular bioenergetics and mitochondrial function through actions that included rapid mitochondrial depolarization, reduced mitochondrial content, and inhibition of oxidative phosphorylation and tricarboxylic acid cycle. LGK974 also broadly altered transcriptional activity, downregulating genes involved in cell cycle, nucleotide metabolism, and ribosomal biogenesis and upregulating genes involved in epithelial-mesenchymal transition, hypoxia, endocytosis, and lysosomes. Autophagy and lysosomal activity were augmented in response to LGK974, which synergistically inhibited tumor cell viability in combination with chloroquine. Autocrine WNT ligand signaling dictates metabolic dependencies in RNF43-mutant PDAC through a combination of transcription dependent and independent effects linked to mitochondrial health and function. Metabolic adaptations to mitochondrial damage and bioenergetic stress represent potential targetable liabilities in combination with PORCNi for the treatment of WNT ligand-addicted PDAC. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35313331      PMCID: PMC9167706          DOI: 10.1158/1535-7163.MCT-21-0623

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.009


  52 in total

Review 1.  The pathways of mitophagy for quality control and clearance of mitochondria.

Authors:  G Ashrafi; T L Schwarz
Journal:  Cell Death Differ       Date:  2012-06-29       Impact factor: 15.828

Review 2.  WNT signaling: an emerging mediator of cancer cell metabolism?

Authors:  Victoria Sherwood
Journal:  Mol Cell Biol       Date:  2014-10-27       Impact factor: 4.272

3.  Structural model of human PORCN illuminates disease-associated variants and drug-binding sites.

Authors:  Jia Yu; Pei-Ju Liao; Weijun Xu; Julie R Jones; David B Everman; Heather Flanagan-Steet; Thomas H Keller; David M Virshup
Journal:  J Cell Sci       Date:  2021-12-20       Impact factor: 5.285

Review 4.  Glycogen synthase kinase-3β: a novel therapeutic target for pancreatic cancer.

Authors:  Li Ding; Daniel D Billadeau
Journal:  Expert Opin Ther Targets       Date:  2020-03-21       Impact factor: 6.902

Review 5.  Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection.

Authors:  Derek J Hausenloy; Derek M Yellon
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

Review 6.  WNT Ligand Dependencies in Pancreatic Cancer.

Authors:  Kristina Y Aguilera; David W Dawson
Journal:  Front Cell Dev Biol       Date:  2021-04-28

7.  Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents.

Authors:  Ciska Verbaanderd; Hannelore Maes; Marco B Schaaf; Vikas P Sukhatme; Pan Pantziarka; Vidula Sukhatme; Patrizia Agostinis; Gauthier Bouche
Journal:  Ecancermedicalscience       Date:  2017-11-23

8.  Temporal dynamics of Wnt-dependent transcriptome reveal an oncogenic Wnt/MYC/ribosome axis.

Authors:  Babita Madan; Nathan Harmston; Gahyathiri Nallan; Alex Montoya; Peter Faull; Enrico Petretto; David M Virshup
Journal:  J Clin Invest       Date:  2018-11-12       Impact factor: 14.808

9.  Common activation of canonical Wnt signaling in pancreatic adenocarcinoma.

Authors:  Marina Pasca di Magliano; Andrew V Biankin; Patrick W Heiser; David A Cano; Pedro J A Gutierrez; Therese Deramaudt; Davendra Segara; Amanda C Dawson; James G Kench; Susan M Henshall; Robert L Sutherland; Andrzej Dlugosz; Anil K Rustgi; Matthias Hebrok
Journal:  PLoS One       Date:  2007-11-07       Impact factor: 3.240

Review 10.  Genetics and biology of pancreatic ductal adenocarcinoma.

Authors:  Haoqiang Ying; Prasenjit Dey; Wantong Yao; Alec C Kimmelman; Giulio F Draetta; Anirban Maitra; Ronald A DePinho
Journal:  Genes Dev       Date:  2016-02-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.